StreetInsider.com News Articles

Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London

Wed, 14 Oct 2026 08:05:00 -0400

PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the company will attend the upcoming 2026 Jefferies Global Healthcare Conference in London on November 18, 2026.

If you are interested in a 1x1 meeting with the Century Therapeutics team during the conference, please reach out to your respective Jefferies representative.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem

Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London

Wed, 14 Oct 2026 08:05:00 -0400

If you are interested in a 1x1 meeting with the Century Therapeutics team during the conference, please reach out to your respective Jefferies representative.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem

Form 8-K Century Therapeutics, For: Oct 02

Fri, 02 Oct 2026 08:19:00 -0400

si-local-file:///var/storage/secattach/20261002/27139087.html

Century Therapeutics shares nonclinical data for iPSC-derived diabetes therapy

Fri, 02 Oct 2026 08:06:23 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) presented nonclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, on Oct. 2, 2026.

The data covered scalable manufacturing, in vivo function, and immune evasion for CNTY-813, which is engineered with the company's Allo-Evasion 5.0 technology and is being developed as a treatment for type 1 diabetes.

In a study lasting over eleven months, CNTY-813 maintained glycemic control in a diabetic mouse model until graft removal. All mice administered with CNTY-813 achieved normoglycemia. The therapy showed glucose-stimulated insulin secretion

Century Therapeutics shares nonclinical data for iPSC-derived diabetes therapy

Fri, 02 Oct 2026 08:06:23 -0400

Century Therapeutics shares nonclinical data for iPSC-derived diabetes therapy

Fri, 02 Oct 2026 08:05:57 -0400

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy.

The data showed CNTY-813 maintained glycemic control in a diabetic mouse model for over eleven months until graft removal. All mice administered with CNTY-813 achieved normoglycemia, and the therapy demonstrated glucose-stimulated insulin secretion potency similar to primary islets.

Five clinical-scale batches produced from Century's Good Manufacturing Practice Master Cell Bank yielded consistent final product profiles across a 29-day manufacturing process. In rat studies, CNTY-813 islets were identified

Century Therapeutics shares nonclinical data for iPSC-derived diabetes therapy

Fri, 02 Oct 2026 08:05:57 -0400

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Fri, 02 Oct 2026 08:05:00 -0400

Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes

CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027

PHILADELPHIA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (“Century”, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced the presentation of nonclinical data for CNTY-813, Century's iPSC-derived islet replacement therapy engineered

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Fri, 02 Oct 2026 08:05:00 -0400

CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Fri, 02 Oct 2026 08:05:00 -0400

CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Fri, 02 Oct 2026 08:05:00 -0400

CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027

Form 144 Century Therapeutics, Filed by: Russotti Gregory

Thu, 24 Sep 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260924/27102768.html

Form 4 Century Therapeutics, For: Sep 14 Filed by: Russotti Gregory

Tue, 15 Sep 2026 18:26:00 -0400

si-local-file:///var/storage/secattach/20260915/27066072.html

Form 4 Century Therapeutics, For: Sep 14 Filed by: Carr Douglas

Tue, 15 Sep 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20260915/27066070.html

Form 4 Century Therapeutics, For: Sep 11 Filed by: Pfeiffenberger Brent

Tue, 15 Sep 2026 18:24:00 -0400

si-local-file:///var/storage/secattach/20260915/27066068.html

Form 144 Century Therapeutics, Filed by: Russotti Gregory

Mon, 14 Sep 2026 15:32:00 -0400

si-local-file:///var/storage/secattach/20260914/27058135.html

Form 144 Century Therapeutics, Filed by: Carr Douglas

Mon, 14 Sep 2026 15:29:00 -0400

si-local-file:///var/storage/secattach/20260914/27058123.html

Form 4 Century Therapeutics, For: Sep 09 Filed by: Truitt Joseph

Thu, 10 Sep 2026 17:49:00 -0400

si-local-file:///var/storage/secattach/20260910/27049588.html

Form 3 Century Therapeutics, For: Sep 09 Filed by: Truitt Joseph

Thu, 10 Sep 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260910/27049585.html

Century Therapeutics names Joseph Truitt to its board of directors

Wed, 09 Sep 2026 16:05:19 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Joseph Truitt to its board of directors, the biotechnology company announced.

Truitt currently serves as chief executive officer and board member of iECURE, Inc., a clinical-stage biotechnology company focused on genome-editing therapies. He also serves as chairman of the board of Larimar Therapeutics (NASDAQ: LRMR) and as a board member of Code Biotherapeutics.

Previously, Truitt was chief executive officer of BioSpecifics Technologies Corp. until its acquisition by Endo International plc in December 2020. Before that, he held several roles at Achillion Pharmaceuticals, including chief commercial officer, chief operating officer, and chief executive officer, prior to

Century Therapeutics names Joseph Truitt to its board of directors

Wed, 09 Sep 2026 16:05:19 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Joseph Truitt to its board of directors, the biotechnology company announced.

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors.

Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing genome-editing therapies for rare, life-threatening genetic diseases. He is Chairman of the Board of Larimar Therapeutics (NASDAQ: LRMR) and a member of the Board of Directors of Code

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400